These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34474520)

  • 1. Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society.
    Kim BK; Kim CH; Min YK
    Endocrinol Metab (Seoul); 2021 Aug; 36(4):909-911. PubMed ID: 34474520
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
    Mori Y; Izumiyama T; Mori N; Aizawa T
    Tohoku J Exp Med; 2021 May; 254(1):57-61. PubMed ID: 34053968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
    Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
    Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Lehmann T; Aeberli D
    Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
    [No Abstract]   [Full Text] [Related]  

  • 10. Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.
    Herath M; Wong P; Milat F
    Intern Med J; 2021 Feb; 51(2):297-298. PubMed ID: 33631850
    [No Abstract]   [Full Text] [Related]  

  • 11. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
    Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
    Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical vertebral fractures following denosumab discontinuation.
    Polyzos SA; Terpos E
    Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
    De Sousa SMC; Jesudason D
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    Rao SD; Qiu S; Dhaliwal R; Bhadada SK
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2111. PubMed ID: 28586451
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    Lamy O; Gonzalez-Rodriguez E; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2112. PubMed ID: 28586456
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.
    Anastasilakis AD; Polyzos SA; Makras P; Aubry-Rozier B; Kaouri S; Lamy O
    J Bone Miner Res; 2017 Jun; 32(6):1291-1296. PubMed ID: 28240371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
    Trovas G
    J Clin Endocrinol Metab; 2017 Mar; 102(3):1086. PubMed ID: 28359104
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series.
    Tripto-Shkolnik L; Liel Y; Yekutiel N; Goldshtein I
    Horm Metab Res; 2021 Mar; 53(3):185-190. PubMed ID: 33588445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
    Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
    Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
    [No Abstract]   [Full Text] [Related]  

  • 20. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
    Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
    Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.